Efficacy and safety of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis.

ABSTRACT:

Background

Asthma remains a global health challenge, with eosinophilic asthma constituting over half of all cases. This refractory phenotype is characterized by persistent type 2 inflammation, where interleukin-5 (IL-5)-mediated eosinophil activity drives disease progression. Although current therapies including high-dose corticosteroids provide partial relief, many severe patients still suffer from uncontrolled symptoms and frequent exacerbations. Mepolizumab, an anti-IL-5 monoclonal antibody, offers targeted intervention, yet its therapeutic effects on lung function remain inconsistently reported across studies. This systematic review aims to clarify mepolizumab's clinical efficacy by analyzing its impact on forced expiratory volume in 1 second (FEV1) improvement, exacerbation re

SUBMITTER: Li Y 

PROVIDER: S-EPMC12688510 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature